MASS icon

908 Devices

6.16 USD
+0.14
2.33%
At close Updated Sep 16, 4:00 PM EDT
Pre-market
After hours
6.16
0.00
0%
1 day
2.33%
5 days
8.07%
1 month
-1.75%
3 months
-14.33%
6 months
34.5%
Year to date
181.28%
1 year
69.23%
5 years
-87.43%
10 years
-87.43%
 

About: 908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.

Employees: 246

0
Funds holding %
of 7,463 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

380% more call options, than puts

Call options by funds: $509K | Put options by funds: $106K

108% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 12

88% more capital invested

Capital invested by funds: $92.3M [Q1] → $174M (+$81.2M) [Q2]

50% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 24

14% more funds holding

Funds holding: 87 [Q1] → 99 (+12) [Q2]

9.51% more ownership

Funds ownership: 58.37% [Q1] → 67.88% (+9.51%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$12
95% upside
Avg. target
$12
95% upside
High target
$12
95% upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Leerink Partners
Puneet Souda
$12
Outperform
Upgraded
5 Aug 2025

Financial journalist opinion

Positive
The Motley Fool
1 month ago
908 Devices (MASS) Q2 Revenue Jumps 14%
908 Devices (MASS) Q2 Revenue Jumps 14%
908 Devices (MASS) Q2 Revenue Jumps 14%
Neutral
Seeking Alpha
1 month ago
908 Devices Inc. (MASS) Q2 2025 Earnings Call Transcript
908 Devices Inc. (NASDAQ:MASS ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Joseph H. Griffith - CFO & Treasurer Kevin J.
908 Devices Inc. (MASS) Q2 2025 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.32 per share a year ago.
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
Neutral
Business Wire
1 month ago
908 Devices Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Outlook
BOSTON--(BUSINESS WIRE)-- #VipIR--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended June 30, 2025. “We executed with urgency and discipline in the second quarter, driving strong top-line growth while advancing key structural initiatives to strengthen our financial profile,” said Kevin J. Knopp, CEO and Co-founder. “We deli.
908 Devices Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Outlook
Neutral
Business Wire
1 month ago
908 Devices Appoints Dr. Brandi Vann, former U.S. Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense, to its Board of Directors
BOSTON--(BUSINESS WIRE)-- #CBRN--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Dr. Brandi Vann to serve on its Board of Directors. During more than 15 years at the U.S. Department of Defense (DoD), Dr. Vann held several leadership positions overseeing nuclear, chemical, and biological defense programs. The company also announces that Jeff George, a veteran biopharma leader, has stepped down from its Board of Directors.
908 Devices Appoints Dr. Brandi Vann, former U.S. Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense, to its Board of Directors
Neutral
Business Wire
1 month ago
908 Devices to Participate in the Canaccord Genuity 45th Annual Growth Conference
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming Canaccord Genuity 45th Annual Growth Conference. 908 Devices' management is scheduled to present on Wednesday, August 13 at 1 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section.
908 Devices to Participate in the Canaccord Genuity 45th Annual Growth Conference
Neutral
Business Wire
1 month ago
908 Devices to Report Second Quarter 2025 Financial Results on August 5, 2025
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced it will report financial results for the second quarter 2025 before market open on Tuesday, August 5, 2025. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available o.
908 Devices to Report Second Quarter 2025 Financial Results on August 5, 2025
Neutral
Business Wire
2 months ago
908 Devices Launches VipIR, a 3-in-1 Handheld Analyzer for Field-Based Chemical Identification of Unknown Bulk Substances
BOSTON--(BUSINESS WIRE)-- #FTIR--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the launch of VipIR, a 3-in-1 handheld analyzer that sets a new standard for rapid and confident field-based chemical identification of unknown bulk solids and liquids, such as narcotics, explosives, and toxic chemicals. VipIR enables customs and border personnel and hazardous response teams to simplify workflows and eliminate guesswork, accelerating decision ma.
908 Devices Launches VipIR, a 3-in-1 Handheld Analyzer for Field-Based Chemical Identification of Unknown Bulk Substances
Positive
Zacks Investment Research
2 months ago
908 Devices (MASS) Upgraded to Buy: Here's What You Should Know
908 Devices (MASS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
908 Devices (MASS) Upgraded to Buy: Here's What You Should Know
Neutral
Business Wire
2 months ago
Asylon Robotics and 908 Devices Deliver Robotic Security at the 2025 Indianapolis 500
NORRISTOWN, Pa.--(BUSINESS WIRE)--Asylon, the U.S. leader in robotic security solutions, in collaboration with 908 Devices, the Indianapolis Metropolitan Police Department, and the Indianapolis Motor Speedway, returned to this year's Indianapolis 500 to deploy its gas-sniffing security robots to help increase the safety and security of those attending the largest single-day sporting event in the world. More than 300,000 people attended this year's event, and Asylon's solution provided unprecede.
Asylon Robotics and 908 Devices Deliver Robotic Security at the 2025 Indianapolis 500
Charts implemented using Lightweight Charts™